Evidence map›Paper›PMID 38992590›Full record

ArticleBMC primary care2024

Provider reported implementation barriers to hepatitis C elimination in Washington State.

Paula Cox-North, Lisa Wiggins, Jon Stockton, Emalie Huriaux, Mary Fliss, Leta Evaskus, Kenneth Pike, Anirban Basu, Pamela Kohler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC primary care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paula Cox-NorthDepartment of Biobehavioral Nursing and Health Informatics, University of Washington, Box 357260, Seattle, Washington, 98195, USA. paulac@uw.edu.
Lisa WigginsDepartment of Child, Family, and Population Health Nursing, University of Washington, Box 357260, Seattle, Washington, 98195, USA.
Jon StocktonDepartment of Health, Washington State, Tumwater, Washington, USA.
Emalie HuriauxDepartment of Health, Washington State, Tumwater, Washington, USA.
Mary FlissWashington State Office of Financial Management, Olympia, WA, USA.
Leta EvaskusWashington State Health Care Authority, Olympia, WA, USA.
Kenneth PikeOffice of Nursing Research, University of Washington, Box 357260, Seattle, Washington, 98195, USA.
Anirban BasuDepartment of Pharmacy, University of Washington, Box 357630, Seattle, Washington, 98195, USA.
Pamela KohlerDepartment of Child, Family, and Population Health Nursing, University of Washington, Box 357260, Seattle, Washington, 98195, USA.

Funding

Scientific/Technical CoreP2CHD042828 · NICHD · UNIVERSITY OF WASHINGTON · PI SARA R. CURRAN · 2017 to 2026
$6.3M
NICHD NIH HHS P2C HD042828
6 · The paper itself

Abstract

backgroundDespite curative treatment options since 2014, only 12% of individuals in Washington State diagnosed with Hepatitis C (HCV) received treatment in 2018. Washington State agencies launched an elimination plan in 2019 to promote access to and delivery of HCV screening and treatment. The purpose of this study is to evaluate provider and health system barriers to successful implementation of HCV screening and treatment across Washington State.

methodsThis is a cross-sectional online survey of 547 physicians, nurse practitioners, physician assistants, and clinical pharmacists who provide care to adult patients in Washington State conducted in 2022. Providers were eligible if they worked in a primary care, infectious disease, gastroenterology, or community health settings. Questions assessed HCV screening and treating practices, implementation barriers, provider knowledge, observed stigma, and willingness to co-manage HCV and substance use disorder. Chi-squared or fishers exact tests compared characteristics of those who did and did not screen or treat.

resultsProvider adoption of screening for HCV was high across the state (96%), with minimal barriers identified. Fewer providers reported treating HCV themselves (28%); most (71%) referred their patients to another provider. Barriers identified by those not treating HCV included knowledge deficit (64%) and lack of organizational support (24%). The barrier most identified in those treating HCV was a lack of treating clinicians (18%). There were few (< 10%) reports of observed stigma in settings of HCV treatment. Most clinicians (95%) were willing to prescribe medication for substance use disorders to those that were using drugs including alcohol.

conclusionDespite widespread screening efforts, there remain barriers to implementing HCV treatment in Washington State. Lack of treating clinicians and clinician knowledge deficit were the most frequently identified barriers to treating HCV. To achieve elimination of HCV by 2030, there is a need to grow and educate the clinician workforce treating HCV.

Indexed as

Hepatitis CMass ScreeningAdultAttitude of Health PersonnelCross-Sectional StudiesDisease EradicationFemaleHealth PersonnelHealth Services AccessibilityHumansMaleMiddle AgedPharmacistsSocial StigmaSurveys and QuestionnairesWashingtonBarriersHepatitis CStigmaSubstance useWashington State

Identifiers

PMID38992590
PMCPMC11241921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.